Treatment of Erythroderma Due to a Drug Reaction

This protocol addresses erythroderma that arises as a direct consequence of a drug reaction — a recognised and clinically significant subset of erythroderma with distinct management considerations.

In case series, drug-related reactions represent the second most frequent cause of erythroderma, accounting for 11.3 to 21.6% of cases.

Management centres on systemic therapy directed at the inflammatory response. The protocol specifies which class of agent is appropriate as a first-line intervention in this setting.

The complete regimen — including agent selection, dosing schedule, and monitoring — is available in the full protocol.